News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alzheon Announces Notice Of Allowance For U.S. Patent For Its Lead Drug Candidate ALZ-801 In Clinical Development For Alzheimer’s Disease


4/15/2014 9:16:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the United States Patent and Trademark Office (US PTO) has issued a notice of allowance for the U.S. Patent Application Number 11/871,639, entitled “Methods, Compounds, Compositions and Vehicles for Delivering 3-Amino-1-Propanesulfonic Acid.” The allowed claims are directed to Alzheon’s lead therapeutic candidate ALZ-801, and protect the ALZ-801 compound, pharmaceutical compositions containing ALZ-801, as well as methods of treating Alzheimer’s disease using ALZ-801. Alzheon is currently advancing ALZ-801 into a confirmatory pivotal Phase 2/3 study in Alzheimer’s disease patients positive for e4 allele of the apolipoprotein E.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
Alzheon
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES